Clearmind Medicine Inc. (NASDAQ:CMND) Sees Large Decrease in Short Interest

Clearmind Medicine Inc. (NASDAQ:CMND) saw a large decrease in short interest during the month of June. As of June 30th, there was short interest totaling 203,361 shares, a decrease of 41.5% from the June 15th total of 347,793 shares. Currently, 20.0% of the company’s stock are sold short. Based on an average daily trading volume, of 824,480 shares, the short-interest ratio is presently 0.2 days.

Insider Buying and Selling at Clearmind Medicine

In related news, major shareholder Financial Lp Hrt sold 22,139 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $3.31, for a total transaction of $73,280.09. Following the completion of the transaction, the insider owned 81,353 shares of the company’s stock, valued at $269,278.43. This trade represents a 21.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders sold 252,615 shares of company stock valued at $117,933.

Clearmind Medicine Price Performance

Shares of Clearmind Medicine stock traded down $0.11 during trading on Friday, hitting $1.88. 122,747 shares of the company’s stock traded hands, compared to its average volume of 1,138,690. Clearmind Medicine has a 1 year low of $1.74 and a 1 year high of $524.00. The business has a 50-day simple moving average of $3.02 and a 200-day simple moving average of $10.11. The stock has a market capitalization of $1.92 million, a P/E ratio of -0.01 and a beta of 0.74.

Clearmind Medicine (NASDAQ:CMND) last announced its quarterly earnings results on Monday, June 15th. The company reported ($6.78) earnings per share (EPS) for the quarter.

Analyst Ratings Changes

Separately, Wall Street Zen raised Clearmind Medicine from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 20th.

Clearmind Medicine Company Profile

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.